Study of INBRX-109 in Conventional Chondrosarcoma

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Conventional Chondrosarcoma

In brief

Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.

Key facts

Study ID

NCT04950075

Run by

Inhibrx Biosciences, Inc

People needed

206

Starts

2021-09-23

Expected to finish

2026-12-01

Last updated by the study team

2026-07-14

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Conventional chondrosarcoma, unresectable (=inoperable) or metastatic.
• Measurable disease by RECISTv1.1. Note: Tumor lesions located in a previously irradiated (or other locally treated) area will be considered measurable, provided there has been clear imaging-based progression of the lesions since the time of treatment.
• Radiologic progression of disease per RECISTv1.1 criteria within 6 months prior to screening for this study.
• Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
• Estimated life expectancy of at least 12 weeks.
• Availability of archival tissue or fresh cancer biopsy are mandatory.

You may not qualify if…

• Any prior exposure to DR5 agonists.
• Allergy or sensitivity to INBRX-109 or known allergies to CHO-produced antibodies.
• Non-conventional chondrosarcoma, e.g., clear-cell, mesenchymal, extraskeletal myxoid, myxoid, and dedifferentiated chondrosarcoma.
• Prior or concurrent malignancies. Exception: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments.
• Chronic liver diseases. Exception: Patients with fatty liver disease are acceptable as long as adequate hepatic function as defined in the inclusion/exclusion criteria is confirmed.
• Evidence or history of multiple sclerosis (MS) or other demyelinating disorders.
• Other exclusion criteria per protocol.

Where it is running

• Precision NextGen Oncology & Research Center — Beverly Hills, California, United States
• University of California, San Francisco (UCSF) — San Francisco, California, United States
• Sarcoma Oncology Center — Santa Monica, California, United States
• University of Colorado — Denver, Colorado, United States
• Yale Cancer Center — New Haven, Connecticut, United States
• Mayo Clinic - Jacksonville — Jacksonville, Florida, United States
• Moffitt Cancer Center — Tampa, Florida, United States
• Northwestern University - Robert H. Lurie Comprehensive Cancer Center — Chicago, Illinois, United States
• Rush Cancer Center — Chicago, Illinois, United States
• University of Iowa — Iowa City, Iowa, United States
• Johns Hopkins — Baltimore, Maryland, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Mayo Clinic Rochester — Rochester, Minnesota, United States
• Washington University School of Medicine - St. Louis — St Louis, Missouri, United States
• Nebraska Methodist Hospital — Omaha, Nebraska, United States
• Norris Cotton Cancer Center — Lebanon, New Hampshire, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Columbia University — New York, New York, United States
• Duke University — Durham, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• University of Oklahoma - Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
• Oregon Health & Science University (OHSU) Knight Cancer Institute — Portland, Oregon, United States
• Mayo Clinic Cancer Center — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.